Pharmacotherapy considerations in patients with HIV and psychiatric disorders: focus on antidepressants and antipsychotics (Q38076073)

28 August 2017

1 reference

title

Pharmacotherapy considerations in patients with HIV and psychiatric disorders: focus on antidepressants and antipsychotics (English)

1 reference

28 August 2017

0 references

Lucas Hill

1

1 reference

PubMed ID

23341158

28 August 2017

Kelly C Lee

series ordinal

2

1 reference

PubMed ID

23341158

28 August 2017

language of work or name

English

0 references

publication date

22 January 2013

1 reference

Annals of Pharmacotherapy

28 August 2017

1 reference

28 August 2017

47

1 reference

28 August 2017

1

1 reference

28 August 2017

75-89

1 reference

A closer look at depression and its relationship to HIV antiretroviral adherence

28 August 2017

1 reference

Depression and HIV/AIDS treatment nonadherence: a review and meta-analysis

21 January 2018

1 reference

Depression and symptomatic response among HIV-infected drug users enrolled in a randomized controlled trial of directly administered antiretroviral therapy

21 January 2018

1 reference

Safety considerations in drug treatment of depression in HIV-positive patients: an updated review

21 January 2018

1 reference

Common mental health problems and antiretroviral therapy adherence

21 January 2018

1 reference

The relationship of post-traumatic stress disorder and depression to antiretroviral medication adherence in persons with HIV.

21 January 2018

1 reference

HIV stigma and depressive symptoms are related to adherence and virological response to antiretroviral treatment among immigrant and indigenous HIV infected patients

21 January 2018

1 reference

Body mass index, depression and sexual transmission risk behaviors among HIV-positive MSM.

21 January 2018

1 reference

Fluoxetine treatment for depression in patients with HIV and AIDS: a randomized, placebo-controlled trial

21 January 2018

1 reference

Structured group therapy and fluoxetine to treat depression in HIV-positive persons

21 January 2018

1 reference

Double-blind comparison of fluoxetine and desipramine in the treatment of depressed women with advanced HIV disease: a pilot study

21 January 2018

1 reference

Efficacy of paroxetine for the treatment of depression in the context of HIV infection.

21 January 2018

1 reference

Citalopram treatment of major depressive disorder in Hispanic HIV and AIDS patients: a prospective study

21 January 2018

1 reference

Effect of imipramine on mood and enumerative measures of immune status in depressed patients with HIV illness.

21 January 2018

1 reference

A multicenter trial of selegiline transdermal system for HIV-associated cognitive impairment.

21 January 2018

1 reference

Testosterone versus fluoxetine for depression and fatigue in HIV/AIDS: a placebo-controlled trial

21 January 2018

1 reference

Placebo-controlled trial of dehydroepiandrosterone (DHEA) for treatment of nonmajor depression in patients with HIV/AIDS.

21 January 2018

1 reference

DHEA and cognition in HIV-positive patients with non-major depression

21 January 2018

1 reference

A double-blind trial of haloperidol, chlorpromazine, and lorazepam in the treatment of delirium in hospitalized AIDS patients

21 January 2018

1 reference

Pilot study with clozapine in patients with HIV-associated psychosis and drug-induced parkinsonism

21 January 2018

1 reference

Treatment of HIV-related psychotic disorders with risperidone: a series of 21 cases.

21 January 2018

1 reference

The successful treatment of mania due to acquired immunodeficiency syndrome using ziprasidone: a case series

21 January 2018

1 reference

Serotonin syndrome in HIV-infected individuals receiving antiretroviral therapy and fluoxetine

21 January 2018

1 reference

Interaction study of the combined use of paroxetine and fosamprenavir-ritonavir in healthy subjects

21 January 2018

1 reference

Induction of CYP2C19 and CYP3A activity following repeated administration of efavirenz in healthy volunteers

21 January 2018

1 reference

Pharmacokinetic interaction between voriconazole and efavirenz at steady state in healthy male subjects

21 January 2018

1 reference

An evaluation of the potential for pharmacokinetic interaction between escitalopram and the cytochrome P450 3A4 inhibitor ritonavir

21 January 2018

1 reference

Short-term exposure to low-dose ritonavir impairs clearance and enhances adverse effects of trazodone.

21 January 2018

1 reference

21 January 2018

1 reference

Efavirenz induces CYP2B6-mediated hydroxylation of bupropion in healthy subjects

21 January 2018

1 reference

Differential sensitivities to risperidone and olanzapine in a human immunodeficiency virus patient

21 January 2018

1 reference

Extrapyramidal symptoms with ritonavir/indinavir plus risperidone

21 January 2018

1 reference

Increased aripiprazole concentrations in an HIV-positive male concurrently taking duloxetine, darunavir, and ritonavir

21 January 2018

1 reference

A randomized evaluation of the effects of six antipsychotic agents on QTc, in the absence and presence of metabolic inhibition

21 January 2018

1 reference

Influence of ritonavir on olanzapine pharmacokinetics in healthy volunteers

21 January 2018

1 reference

Antiretroviral therapy-induced psychosis: case report and brief review of the literature

21 January 2018

1 reference

Comparison of neuropsychiatric side effects in an observational cohort of efavirenz- and protease inhibitor-treated patients

21 January 2018

1 reference

Extrapyramidal symptoms due to dopamine-blocking agents in patients with AIDS encephalopathy

21 January 2018

1 reference

Atypical antipsychotics and metabolic dysregulation: evaluating the risk/benefit equation and improving the standard of care

21 January 2018

1 reference

Metabolic syndrome and associated cardiovascular risk factors in the treatment of persons with human immunodeficiency virus and severe mental illness

21 January 2018

1 reference

Body fat redistribution and metabolic abnormalities in HIV-infected patients on highly active antiretroviral therapy: novel insights into pathophysiology and emerging opportunities for treatment.

21 January 2018

1 reference

HIV-1 infection and neurocognitive impairment in the current era.

21 January 2018

1 reference

HIV dementia: the role of the basal ganglia and dopaminergic systems

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1345/APH.1R343

1 reference

28 August 2017

1 reference

PubMed ID

23341158